{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:58:24Z","timestamp":1795111104401,"version":"4.10.3"},"reference-count":292,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01921-5","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:05:24Z","timestamp":1767924324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7408-0984","authenticated-orcid":false,"given":"Julia R.","family":"Bacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2505-770X","authenticated-orcid":false,"given":"Stamatia","family":"Karagianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-0834","authenticated-orcid":false,"given":"Zampeta-Sofia","family":"Alexopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5421-8038","authenticated-orcid":false,"given":"Shirine","family":"Moukaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8448-8678","authenticated-orcid":false,"given":"Claudia","family":"Tato-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0798-6250","authenticated-orcid":false,"given":"Prithvi","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Aslanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-4834","authenticated-orcid":false,"given":"Sandar","family":"Aye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5435-6773","authenticated-orcid":false,"given":"Ana Sabsil Lopez","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-5217","authenticated-orcid":false,"given":"Ayesha","family":"Fawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7869-8192","authenticated-orcid":false,"given":"Aitana","family":"Sogorb-Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1781","authenticated-orcid":false,"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-3635","authenticated-orcid":false,"given":"Ross W.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"3","key":"1921_CR1","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/ijms23031851","volume":"23","author":"RNL Lamptey","year":"2022","unstructured":"Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. IJMS. 2022;23(3):1851.","journal-title":"IJMS"},{"issue":"4","key":"1921_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693\u2013714.","journal-title":"Cell"},{"key":"1921_CR3","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u2013821.","DOI":"10.1002\/alz.13809"},{"key":"1921_CR4","doi-asserted-by":"crossref","unstructured":"L\u00f3pez OL, DeKosky ST. Clinical symptoms in Alzheimer\u2019s disease. Handb Clin Neurol. 2008;89:207\u201316.","DOI":"10.1016\/S0072-9752(07)01219-5"},{"issue":"3","key":"1921_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/diagnostics13030573","volume":"13","author":"N Shusharina","year":"2023","unstructured":"Shusharina N, Yukhnenko D, Botman S, Sapunov V, Savinov V, Kamyshov G, et al. Modern methods of diagnostics and treatment of neurodegenerative diseases and depression. Diagnostics. 2023;13(3):573.","journal-title":"Diagnostics"},{"issue":"6","key":"1921_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"3","key":"1921_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018;243(3):213\u201321.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"1921_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319.","journal-title":"Nat Aging"},{"key":"1921_CR9","doi-asserted-by":"crossref","unstructured":"Pascoal TA, Aguzzoli CS, Lussier FZ, Crivelli L, Suemoto CK, Fortea J, et al. Insights into the use of biomarkers in clinical trials in alzheimer\u2019s disease. eBioMedicine. 2024;108:105322.","DOI":"10.1016\/j.ebiom.2024.105322"},{"issue":"7","key":"1921_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1921_CR11","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.lanhl.2024.07.013","volume":"5","author":"M Sch\u00f6ll","year":"2024","unstructured":"Sch\u00f6ll M, Verberk IMW, Del Campo M, Delaby C, Therriault J, Chong JR, et al. Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease. Lancet Healthy Longev. 2024;5(10):100630.","journal-title":"Lancet Healthy Longev"},{"key":"1921_CR12","doi-asserted-by":"crossref","unstructured":"Lista S, Mapstone M, Caraci F, Emanuele E, L\u00f3pez-Ortiz S, Mart\u00edn-Hern\u00e1ndez J et al. A critical appraisal of blood-based biomarkers for alzheimer\u2019s disease. Ageing Res Rev. 2024;96:102290.","DOI":"10.1016\/j.arr.2024.102290"},{"issue":"1","key":"1921_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jamaneurol.2024.3533","volume":"82","author":"CM Erickson","year":"2025","unstructured":"Erickson CM, Wexler A, Largent EA. Digital biomarkers for neurodegenerative disease. JAMA Neurol. 2025;82(1):5\u20136.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1921_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11020215","volume":"11","author":"DA McGrowder","year":"2021","unstructured":"McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, et al. Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease: current evidence and future perspectives. Brain Sci. 2021;11(2):215.","journal-title":"Brain Sci"},{"issue":"1","key":"1921_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","volume":"16","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics. Mol Neurodegeneration. 2021;16(1):10.","journal-title":"Mol Neurodegeneration"},{"key":"1921_CR16","doi-asserted-by":"crossref","unstructured":"Farotti L, Sepe FN, Toja A, Rinaldi R, Parnetti L. Differential diagnosis between Alzheimer\u2019s disease and other dementias: role of cerebrospinal fluid biomarkers. Clin Biochem. 2019;72:24\u20139.","DOI":"10.1016\/j.clinbiochem.2019.04.011"},{"issue":"22","key":"1921_CR17","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.3390\/ijms20225536","volume":"20","author":"A Lloret","year":"2019","unstructured":"Lloret A, Esteve D, Lloret M-A, Cervera-Ferri A, Lopez B, Nepomuceno M, et al. When does Alzheimer\u2032s disease really start? The role of biomarkers. IJMS. 2019;20(22):5536.","journal-title":"IJMS"},{"issue":"1","key":"1921_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alz Res Ther. 2019;11(1):34.","journal-title":"Alz Res Ther"},{"issue":"1","key":"1921_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01314-6","volume":"15","author":"B Dubois","year":"2023","unstructured":"Dubois B, Von Arnim CAF, Burnie N, Bozeat S, Cummings J. Biomarkers in Alzheimer\u2019s disease: role in early and differential diagnosis and recognition of atypical variants. Alz Res Ther. 2023;15(1):175.","journal-title":"Alz Res Ther"},{"issue":"1","key":"1921_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41380-024-02709-z","volume":"30","author":"TR Hunter","year":"2025","unstructured":"Hunter TR, Santos LE, Tovar-Moll F, De Felice FG. Alzheimer\u2019s disease biomarkers and their current use in clinical research and practice. Mol Psychiatry. 2025;30(1):272\u201384.","journal-title":"Mol Psychiatry"},{"issue":"10","key":"1921_CR21","doi-asserted-by":"publisher","first-page":"8976","DOI":"10.3390\/ijms24108976","volume":"24","author":"V Papaliagkas","year":"2023","unstructured":"Papaliagkas V, Kalinderi K, Vareltzis P, Moraitou D, Papamitsou T, Chatzidimitriou M. CSF biomarkers in the early diagnosis of mild cognitive impairment and Alzheimer\u2019s disease. IJMS. 2023;24(10):8976.","journal-title":"IJMS"},{"issue":"10","key":"1921_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100629","volume":"22","author":"CE Teunissen","year":"2023","unstructured":"Teunissen CE, Kimble L, Bayoumy S, Bolsewig K, Burtscher F, Coppens S, et al. Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias. Mol Cell Proteomics. 2023;22(10):100629.","journal-title":"Mol Cell Proteomics"},{"key":"1921_CR23","doi-asserted-by":"crossref","unstructured":"Barro C, Zetterberg H. The blood biomarkers puzzle \u2013 A review of protein biomarkers in neurodegenerative diseases. J Neurosci Methods. 2021;361:109281.","DOI":"10.1016\/j.jneumeth.2021.109281"},{"issue":"4","key":"1921_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.14283\/jpad.2022.85","volume":"9","author":"D Angioni","year":"2022","unstructured":"Angioni D, Delrieu J, Hansson O, Fillit H, Aisen P, Cummings J, et al. Blood biomarkers from research use to clinical practice: what must be done? A report from the EU\/US CTAD task force. J Prev Alzheimers Dis. 2022;9(4):569\u201379.","journal-title":"J Prev Alzheimers Dis"},{"key":"1921_CR25","doi-asserted-by":"crossref","unstructured":"Baird AL, Westwood S, Lovestone S. Blood-Based proteomic biomarkers of alzheimer\u2019s disease pathology. Front Neurol. 2015;6:236.","DOI":"10.3389\/fneur.2015.00236"},{"issue":"1","key":"1921_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/ane.13628","volume":"146","author":"H Zetterberg","year":"2022","unstructured":"Zetterberg H, Schott JM. Blood biomarkers for Alzheimer\u2019s disease and related disorders. Acta Neurol Scand. 2022;146(1):51\u20135.","journal-title":"Acta Neurol Scand"},{"issue":"7691","key":"1921_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature"},{"issue":"11","key":"1921_CR28","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375\u201382.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1921_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1921_CR30","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, et al. Comparison of plasma phosphorylated Tau species with amyloid and Tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78(9):1108\u201317.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1921_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324.","journal-title":"Acta Neuropathol"},{"issue":"Suppl 1","key":"1921_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","volume":"6","author":"K Blennow","year":"2017","unstructured":"Blennow K. A review of fluid biomarkers for Alzheimer\u2019s disease: moving from CSF to blood. Neurol Ther. 2017;6(Suppl 1):15\u201324.","journal-title":"Neurol Ther"},{"issue":"6","key":"1921_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595\u20139.","journal-title":"Nat Biotechnol"},{"key":"1921_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neulet.2014.04.041","volume":"573","author":"J Pannee","year":"2014","unstructured":"Pannee J, T\u00f6rnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, et al. The amyloid-\u03b2 degradation pattern in plasma\u2014a possible tool for clinical trials in Alzheimer\u2019s disease. Neurosci Lett. 2014;573:7\u201312.","journal-title":"Neurosci Lett"},{"issue":"3","key":"1921_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2183\/pjab.90.104","volume":"90","author":"N Kankeo","year":"2014","unstructured":"Kankeo N, Yamamoto R, Sato TA, Tanaka K. Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(3):104\u201317.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"4","key":"1921_CR36","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/alz.13697","volume":"20","author":"H Huber","year":"2024","unstructured":"Huber H, Blennow K, Zetterberg H, Boada M, Jeromin A, Weninger H, et al. Biomarkers of Alzheimer\u2019s disease and neurodegeneration in dried blood spots\u2014a new collection method for remote settings. Alzheimers Dement. 2024;20(4):2340\u201352.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1921_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12145","volume":"13","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n J, Ashton NJ, Blennow K, Zetterberg H. Blood neurofilament light in remote settings: alternative protocols to support sample collection in challenging pre-analytical conditions. Alz & Dem Diag Ass & Dis Mo. 2021;13(1):e12145.","journal-title":"Alz & Dem Diag Ass & Dis Mo"},{"issue":"1","key":"1921_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1176\/appi.focus.11.1.96","volume":"11","author":"MS Albert","year":"2013","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. FOC. 2013;11(1):96\u2013106.","journal-title":"FOC"},{"issue":"3","key":"1921_CR39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1921_CR40","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"1921_CR41","unstructured":"Fujirebio. Lumipulse\u00ae G \u03b2-Amyloid Ratio (1\u201342\/1\u201340) in vitro diagnostic test receives marketing authorization for the assessment of Alzheimer\u2019s disease. Fujirebio; 2022. Available from: https:\/\/www.fujirebio.com\/en\/news-events\/lumipulser-g-bamyloid-ratio-142140-in-vitro-diagnostic-test-receives-fda-marketing"},{"key":"1921_CR42","unstructured":"Roche. Roche Alzheimer\u2019s disease Cerebrospinal Fluid (CSF) assays receive FDA clearance, supporting more accurate and timely diagnosis. Roche; 2023. Available from: https:\/\/diagnostics.roche.com\/us\/en\/news-listing\/2022\/roche-alzheimers-disease-cerebrospinal-fluid-assays-receive-fda-clearance.html"},{"key":"1921_CR43","unstructured":"Roche. Roche receives FDA clearance for additional Alzheimer\u2019s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making. Roche. 2023. Available from: https:\/\/diagnostics.roche.com\/us\/en\/news-listing\/2023\/roche-fda-clearance-additional-alzheimers-disease-cerebrospinal-fluid-ttau.html#:~:text=The%20Elecsys%C2%AE%20beta-Amyloid,reflective%20of%20the%20main%20Alzheimer\u2019s"},{"issue":"11","key":"1921_CR44","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","volume":"14","author":"LM Shaw","year":"2018","unstructured":"Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(11):1505\u201321.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1921_CR45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2022-329530","volume":"94","author":"J Hazan","year":"2023","unstructured":"Hazan J, Wing M, Liu KY, Reeves S, Howard R. Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94(2):113\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1921_CR46","unstructured":"U.S. Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer\u2019s disease [Internet]. Silver Spring (MD): FDA; 2025 May 16 [cited 2025 May 29]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease"},{"key":"1921_CR47","unstructured":"Roche Diagnostics. Roche granted FDA Breakthrough Device Designation for pTau217 blood test to support earlier Alzheimer\u2019s disease diagnosis [Internet]. 2024 Apr 11 [cited 2025 Jan 2]. Available from: https:\/\/diagnostics.roche.com\/us\/en\/news-listing\/2024\/roche-granted-fda-breakthrough-device-designation-ptau217-blood-test-support-earlier-alzheimers-disease-diagnosis.html"},{"key":"1921_CR48","unstructured":"C2N Diagnostics. C\u2082N Diagnostics Receives Breakthrough Device Designation from U.S. FDA for Blood Test to Screen for Alzheimer\u2019s Disease Risk [Internet]. 2019 Jan 9 [cited 2025 Jan 2]. Available from: https:\/\/c2n.com\/news-releases\/2019\/01\/29\/2019-1-24-c2n-diagnostics-receives-breakthrough-device-designation-from-us-fda-for-blood-test-to-screen-for-alzheimers-disease-risk"},{"key":"1921_CR49","unstructured":"Quanterix. Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based. pTau-181 Assay for Alzheimer\u2019s Disease [Internet]. 2021 Oct 11 [cited 2025 Apr 21]. Available from: https:\/\/www.quanterix.com\/press-releases\/quanterix-granted-breakthrough-device-designation-from-u-s-fda-for-blood-based-ptau-181-assay-for-alzheimers-disease\/"},{"key":"1921_CR50","unstructured":"Quanterix. Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based. p-Tau 217 Test for Alzheimer\u2019s Disease [Internet]. 2024 Jan 30 [cited 2025 Apr 21]. Available from: https:\/\/www.quanterix.com\/press-releases\/quanterix-granted-breakthrough-device-designation-from-u-s-fda-for-blood-based-p-tau-217-test-for-alzheimers-disease\/"},{"issue":"4","key":"1921_CR51","doi-asserted-by":"publisher","first-page":"e228392","DOI":"10.1001\/jamanetworkopen.2022.8392","volume":"5","author":"Y Hu","year":"2022","unstructured":"Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, et al. Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment. JAMA Netw Open. 2022;5(4):e228392.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1921_CR52","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry\u2010based test with algorithm combining %p\u2010tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 2024;20(5):3179\u201392.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1921_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255\u201363.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1921_CR54","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40120-024-00658-x","volume":"13","author":"SE Ankeny","year":"2024","unstructured":"Ankeny SE, Bacci JR, Decourt B, Sabbagh MN, Mielke MM. Navigating the landscape of plasma biomarkers in Alzheimer\u2019s disease: focus on past, present, and future clinical applications. Neurol Ther. 2024;13(6):1541\u201357.","journal-title":"Neurol Ther"},{"issue":"1","key":"1921_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","volume":"16","author":"T West","year":"2021","unstructured":"West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, et al. A blood-based diagnostic test incorporating plasma A\u03b242\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener. 2021;16(1):30.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1921_CR56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000100926","volume":"23","author":"O Hansson","year":"2007","unstructured":"Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer\u2019s disease using the CSF A\u03b242\/A\u03b240 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23(5):316\u201320.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"1921_CR57","doi-asserted-by":"publisher","first-page":"19024","DOI":"10.1038\/s41598-019-54204-z","volume":"9","author":"K Blennow","year":"2019","unstructured":"Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, et al. Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2(1\u201342), pTau and tTau CSF immunoassays. Sci Rep. 2019;9(1):19024.","journal-title":"Sci Rep"},{"issue":"3","key":"1921_CR58","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386.","journal-title":"Nat Med"},{"issue":"4","key":"1921_CR59","volume":"15","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Wu W, Ma X, Wu J, Liang X, Zhou X, et al. Plasma p-tau217, p\u2010tau181, and NfL as early indicators of dementia risk in a community cohort: the Shanghai Aging Study. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2023;15(4):e12514.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"12","key":"1921_CR60","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28(12):2555\u201362.","journal-title":"Nat Med"},{"key":"1921_CR61","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Warmenhoven N, Anastasi F, Pilotto A, Janelidze S, Tideman P, et al. Plasma phospho-tau217 for alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med. 2025;31(6):2036-43.","DOI":"10.1038\/s41591-025-03622-w"},{"issue":"1","key":"1921_CR62","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Ferrer R, Carmona-Iragui M, et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21\u201342 and A\u03b21\u201340 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alz Res Therapy. 2024;16(1):139.","journal-title":"Alz Res Therapy"},{"issue":"13","key":"1921_CR63","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IOC, Dick KM, Brotherhood E, Gordon E, Fellows A, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329\u201336.","journal-title":"Neurology"},{"issue":"2","key":"1921_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","volume":"90","author":"F Verde","year":"2019","unstructured":"Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157\u201364.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1921_CR65","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","volume":"92","author":"BS Rauchmann","year":"2021","unstructured":"Rauchmann BS, Schneider-Axmann T, Perneczky R. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A\u03b2-PET and cognition. J Neurol Neurosurg Psychiatry. 2021;92(12):1289\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1921_CR66","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"DIA Network","year":"2019","unstructured":"Network DIA, Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383.","journal-title":"Nat Med"},{"issue":"5","key":"1921_CR67","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. For the alzheimer\u2019s disease neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1921_CR68","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Janelidze S, Palmqvist S, Svenningsson AL, Stomrud E, et al. Plasma biomarkers of alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12(1):3555.","journal-title":"Nat Commun"},{"key":"1921_CR69","unstructured":"ClinicalTrials.gov. AHEAD 3\u201345 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer\u2019s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer\u2019s Disease and Intermediate Amyloid [Internet]. 2025 Jan 01 [cited 2025 Jan 02]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04468659"},{"key":"1921_CR70","unstructured":"Mielke MM, Anderson M, Ashford JW, Jeromin A, Lin P, Rosen A et al. Considerations for widespread implementation of blood-based biomarkers of Alzheimer\u2019s disease. Alzheimers Dement. 2024;alz.14150."},{"issue":"11","key":"1921_CR71","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1002\/alz.14219","volume":"20","author":"A Leuzy","year":"2024","unstructured":"Leuzy A, Heeman F, Bosch I, Len\u00e9r F, Dottori M, Quitz K, et al. REAL AD\u2014validation of a realistic screening approach for early Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(11):8172\u201382.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1921_CR72","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al. Performance of plasma phosphorylated Tau 181 and 217 in the community. Nat Med. 2022;28(7):1398\u2013405.","journal-title":"Nat Med"},{"issue":"6","key":"1921_CR73","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen JA, Campbell MR, Algeciras-Schimnich A, Vemuri P, Graff-Radford J, Machulda MM, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128\u201340.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1921_CR74","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated Tau to total Tau ratios. JAMA Neurol. 2023;80(5):516\u201322.","journal-title":"JAMA Neurol"},{"key":"1921_CR75","doi-asserted-by":"publisher","DOI":"10.14283\/jarlife.2024.1","author":"KM Hayden","year":"2024","unstructured":"Hayden KM, Mielke MM, Evans JK, Neiberg R, Molina-Henry D, Culkin M, et al. Association between modifiable risk factors and levels of blood-based biomarkers of Alzheimer\u2019s and related dementias in the Look AHEAD cohort. The Journal of Aging Research & Lifestyle. 2024. https:\/\/doi.org\/10.14283\/jarlife.2024.1.","journal-title":"The Journal of Aging Research & Lifestyle"},{"issue":"1","key":"1921_CR76","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/alz.12647","volume":"19","author":"SE O\u2019Bryant","year":"2023","unstructured":"O\u2019Bryant SE, Petersen M, Hall J, Johnson LA, Team for the H-HS. Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: important considerations for clinical trials and practice. Alzheimers Dement. 2023;19(1):36\u201343.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1921_CR77","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","volume":"81","author":"WS Brum","year":"2024","unstructured":"Brum WS, Docherty KF, Ashton NJ, Zetterberg H, Hansson O, McMurray JJV, et al. Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurol. 2024;81(2):197.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1921_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100058","volume":"12","author":"Z Wu","year":"2025","unstructured":"Wu Z, Mielke MM, Murray AM, Phung J, Owen A, Woods RL, et al. The impact of pre-analytical factors on plasma biomarkers for Alzheimer\u2019s disease: the ASPREE Healthy Ageing Biobank. The Journal of Prevention of Alzheimer\u2019s Disease. 2025;12(4):100058.","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"8","key":"1921_CR79","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood\u2010based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484\u201397.","journal-title":"Alzheimers Dement"},{"key":"1921_CR80","unstructured":"US Food and Drug Administration. Center for devices and radiological health. Evaluation of automatic class III designation for Lumipulse G \u03b2-amyloid ratio (1\u201342\/1\u201340) decision summary. 2022. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN200072.pdf"},{"key":"1921_CR81","unstructured":"US Food and Drug Administration. Center for Devices and Radiological Health. Elecsys \u03b2-amyloid (1\u201342) CSF II, Elecsys phospho-tau (181P) CSF: 510(k) substantial equivalence determination decision summary. 2022. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K221842.pdf"},{"key":"1921_CR82","unstructured":"US Food and Drug Administration, Center for Devices and Radiological Health. Elecsys \u03b2-amyloid (1\u201342) CSF II, Elecsys total-tau CSF substantial equivalence determination decision summary. 2023. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/K231348.pdf"},{"key":"1921_CR83","unstructured":"C2N Diagnostics. The PrecivityAD Blood Test Specifications. C2N Diagnostics. 2024. Available from: https:\/\/precivityad.com\/s\/PAD_new_cutmlMarch28th.pdf"},{"key":"1921_CR84","unstructured":"C2N Diagnostics. The PrecivityAD2 Blood Test Specifications. C2N Diagnostics. 2023. Available from: https:\/\/precivityad.com\/s\/The_PrecivityAD2_Blood_Test_Specifications_27July2023-6-5.pdf"},{"issue":"2","key":"1921_CR85","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","volume":"6","author":"GB Frisoni","year":"2010","unstructured":"Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67\u201377.","journal-title":"Nat Rev Neurol"},{"key":"1921_CR86","doi-asserted-by":"crossref","unstructured":"Georgakas JE, Howe MD, Thompson LI, Riera NM, Riddle MC. Biomarkers of alzheimer\u2019s disease: Past, present and future clinical use. Biomark Neuropsychiatry. 2023;8(1):100063.","DOI":"10.1016\/j.bionps.2023.100063"},{"issue":"1","key":"1921_CR87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.42.1.183","volume":"42","author":"CR Jack","year":"1992","unstructured":"Jack CR, Petersen RC, O\u2019Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer\u2019s disease. Neurology. 1992;42(1):183\u20138.","journal-title":"Neurology"},{"issue":"3","key":"1921_CR88","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0306-4522(99)00476-5","volume":"95","author":"M Bobinski","year":"1999","unstructured":"Bobinski M, De Leon MJ, Wegiel J, DeSanti S, Convit A, Saint Louis LA, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer\u2019s disease. Neuroscience. 1999;95(3):721\u20135.","journal-title":"Neuroscience"},{"issue":"10","key":"1921_CR89","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.neurobiolaging.2009.11.008","volume":"32","author":"LK Ferreira","year":"2011","unstructured":"Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV. Neurostructural predictors of Alzheimer\u2019s disease: a meta-analysis of VBM studies. Neurobiol Aging. 2011;32(10):1733\u201341.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"1921_CR90","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/ana.20503","volume":"57","author":"C Zarow","year":"2005","unstructured":"Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al. Correlates of hippocampal neuron number in Alzheimer\u2019s disease and ischemic vascular dementia. Ann Neurol. 2005;57(6):896\u2013903.","journal-title":"Ann Neurol"},{"issue":"4","key":"1921_CR91","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/brain\/awm016","volume":"130","author":"A-T Du","year":"2006","unstructured":"Du A-T, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, et al. Different regional patterns of cortical thinning in Alzheimer\u2019s disease and frontotemporal dementia. Brain. 2006;130(4):1159\u201366.","journal-title":"Brain"},{"issue":"11","key":"1921_CR92","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/jnnp-2016-314978","volume":"88","author":"L Harper","year":"2017","unstructured":"Harper L, Bouwman F, Burton EJ, Barkhof F, Scheltens P, O\u2019Brien JT, et al. Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. J Neurol Neurosurg Psychiatry. 2017;88(11):908\u201316.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1921_CR93","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.3174\/ajnr.A7586","volume":"43","author":"PM Cogswell","year":"2022","unstructured":"Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR, Poussaint TY, et al. Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol. 2022;43(9):E19\u201335.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"1921_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2023;9(2):e12385.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"9","key":"1921_CR95","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/jnnp-2024-333468","volume":"95","author":"R Dobson","year":"2024","unstructured":"Dobson R, Patterson K, Malik R, Mandal U, Asif H, Humphreys R, et al. Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2024;95(9):796\u2013803.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1921_CR96","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.neurobiolaging.2014.02.021","volume":"35","author":"LEM Wisse","year":"2014","unstructured":"Wisse LEM, Biessels GJ, Heringa SM, Kuijf HJ, Koek D, Luijten (H)L. Hippocampal subfield volumes at 7T in early alzheimer\u2019s disease and normal aging. Neurobiol Aging. 2014;35(9):2039\u201345.","journal-title":"Neurobiol Aging"},{"key":"1921_CR97","doi-asserted-by":"crossref","unstructured":"Boutet C, Chupin M, Leh\u00e9ricy S, Marrakchi-Kacem L, Epelbaum S, Poupon C et al. Detection of volume loss in hippocampal layers in alzheimer\u2019s disease using 7 T MRI: A feasibility study. NeuroImage: Clin. 2014;5:341\u20138.","DOI":"10.1016\/j.nicl.2014.07.011"},{"key":"1921_CR98","doi-asserted-by":"crossref","unstructured":"Cosottini M, Roccatagliata L. Neuroimaging at 7 T: are we ready for clinical transition? Eur Radiol Exp. 2021;5(1):37.","DOI":"10.1186\/s41747-021-00234-0"},{"issue":"1","key":"1921_CR99","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/jmri.28408","volume":"57","author":"TC Arnold","year":"2023","unstructured":"Arnold TC, Freeman CW, Litt B, Stein JM. Low-field MRI: clinical promise and challenges. Magn Reson Imaging. 2023;57(1):25\u201344.","journal-title":"Magn Reson Imaging"},{"key":"1921_CR100","doi-asserted-by":"crossref","unstructured":"Sarracanie M, Salameh N, Low-Field MRI. How low can we go? A fresh view on an old debate. Front Phys. 2020;8:172.","DOI":"10.3389\/fphy.2020.00172"},{"issue":"3","key":"1921_CR101","doi-asserted-by":"publisher","first-page":"e220522","DOI":"10.1148\/radiol.220522","volume":"306","author":"JE Iglesias","year":"2023","unstructured":"Iglesias JE, Schleicher R, Laguna S, Billot B, Schaefer P, McKaig B, et al. Quantitative brain morphometry of portable low-field-strength MRI using super-resolution machine learning. Radiology. 2023;306(3):e220522.","journal-title":"Radiology"},{"issue":"1","key":"1921_CR102","doi-asserted-by":"publisher","first-page":"10488","DOI":"10.1038\/s41467-024-54972-x","volume":"15","author":"AJ Sorby-Adams","year":"2024","unstructured":"Sorby-Adams AJ, Guo J, Laso P, Kirsch JE, Zabinska J, Garcia Guarniz A-L, et al. Portable, low-field magnetic resonance imaging for evaluation of Alzheimer\u2019s disease. Nat Commun. 2024;15(1):10488.","journal-title":"Nat Commun"},{"issue":"5","key":"1921_CR103","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.neuron.2020.01.041","volume":"105","author":"FX Shen","year":"2020","unstructured":"Shen FX, Wolf SM, Gonzalez RG, Garwood M. Ethical issues posed by field research using highly portable and cloud-enabled neuroimaging. Neuron. 2020;105(5):771\u20135.","journal-title":"Neuron"},{"key":"1921_CR104","doi-asserted-by":"crossref","unstructured":"Shen FX, Wolf SM, Bhavnani S, Deoni S, Elison JT, Fair D et al. Emerging ethical issues Raised by highly portable MRI research in remote and resource-limited international settings. NeuroImage. 2021;238118210.","DOI":"10.1016\/j.neuroimage.2021.118210"},{"key":"1921_CR105","doi-asserted-by":"crossref","unstructured":"Elliott ML, Hanford LC, Hamadeh A, Hilbert T, Kober T, Dickerson BC, et al. Brain morphometry in older adults with and without dementia using extremely rapid structural scans. NeuroImage. 2023;276:120173.","DOI":"10.1016\/j.neuroimage.2023.120173"},{"issue":"10","key":"1921_CR106","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1002\/alz.14166","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Arani A, Borowski BJ, Cash DM, Crawford K, Das SR, et al. Overview of ADNI MRI. Alzheimers Dement. 2024;20(10):7350\u201360.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1921_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081093","volume":"8","author":"J Acosta-Cabronero","year":"2013","unstructured":"Acosta-Cabronero J, Williams GB, Cardenas-Blanco A, Arnold RJ, Lupson V, Nestor PJ. In vivo quantitative susceptibility mapping (QSM) in Alzheimer\u2019s disease. PLoS One. 2013;8(11):e81093.","journal-title":"PLoS One"},{"key":"1921_CR108","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.nicl.2017.08.019","volume":"16","author":"H-G Kim","year":"2017","unstructured":"Kim H-G, Park S, Rhee HY, Lee KM, Ryu C-W, Rhee SJ, et al. Quantitative susceptibility mapping to evaluate the early stage of Alzheimer\u2019s disease. Neuroimage Clin. 2017;16:429\u201338.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"1921_CR109","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13195-023-01281-y","volume":"15","author":"RL Gallagher","year":"2023","unstructured":"Gallagher RL, Koscik RL, Moody JF, Vogt NM, Adluru N, Kecskemeti SR, et al. Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status. Alz Res Ther. 2023;15(1):180.","journal-title":"Alz Res Ther"},{"key":"1921_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109243","volume":"131","author":"S Tiepolt","year":"2020","unstructured":"Tiepolt S, Rullmann M, Jochimsen TH, Gertz H-J, Schroeter ML, Patt M, et al. Quantitative susceptibility mapping in \u03b2-Amyloid PET-stratified patients with dementia and healthy controls \u2013 a hybrid PET\/MRI study. Eur J Radiol. 2020;131:109243.","journal-title":"Eur J Radiol"},{"key":"1921_CR111","doi-asserted-by":"publisher","first-page":"120357","DOI":"10.1016\/j.neuroimage.2023.120357","volume":"280","author":"M Ahmed","year":"2023","unstructured":"Ahmed M, Chen J, Arani A, Senjem ML, Cogswell PM, Jack CR, et al. The diamagnetic component map from quantitative susceptibility mapping (QSM) source separation reveals pathological alteration in Alzheimer\u2019s disease-driven neurodegeneration. Neuroimage. 2023;280:120357.","journal-title":"Neuroimage"},{"issue":"8","key":"1921_CR112","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/brain\/awx137","volume":"140","author":"S Ayton","year":"2017","unstructured":"Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY, et al. Cerebral quantitative susceptibility mapping predicts amyloid-\u03b2-related cognitive decline. Brain. 2017;140(8):2112\u20139.","journal-title":"Brain"},{"key":"1921_CR113","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.neuroimage.2019.02.019","volume":"191","author":"N-J Gong","year":"2019","unstructured":"Gong N-J, Dibb R, Bulk M, Van Der Weerd L, Liu C. Imaging beta amyloid aggregation and iron accumulation in Alzheimer\u2019s disease using quantitative susceptibility mapping MRI. Neuroimage. 2019;191:176\u201385.","journal-title":"Neuroimage"},{"issue":"2","key":"1921_CR114","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3233\/JAD-180118","volume":"64","author":"NB Bank","year":"2018","unstructured":"Bank NB, Tiepolt S, Sch\u00e4fer A, Rullmann M, Roggenhofer E, Gertz H-J, et al. Quantitative susceptibility mapping of Amyloid-\u03b2 aggregates in Alzheimer\u2019s disease with 7T MR. JAD. 2018;64(2):393\u2013404.","journal-title":"JAD"},{"key":"1921_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2019.116389","volume":"207","author":"Y Chen","year":"2020","unstructured":"Chen Y, Jakary A, Avadiappan S, Hess CP, Lupo JM. QSMGAN: improved quantitative susceptibility mapping using 3D generative adversarial networks with increased receptive field. Neuroimage. 2020;207:116389.","journal-title":"Neuroimage"},{"key":"1921_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117433","volume":"224","author":"PM Cogswell","year":"2021","unstructured":"Cogswell PM, Wiste HJ, Senjem ML, Gunter JL, Weigand SD, Schwarz CG, et al. Associations of quantitative susceptibility mapping with Alzheimer\u2019s disease clinical and imaging markers. Neuroimage. 2021;224:117433.","journal-title":"Neuroimage"},{"issue":"3","key":"1921_CR117","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306\u201319.","journal-title":"Ann Neurol"},{"issue":"4","key":"1921_CR118","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"NIA-AA research","year":"2018","unstructured":"NIA-AA research. Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1921_CR119","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Pike KE, Ch\u00e9telat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181\u201392.","journal-title":"Ann Neurol"},{"issue":"1","key":"1921_CR120","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-020-00612-7","volume":"12","author":"PNE Young","year":"2020","unstructured":"Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, et al. Imaging biomarkers in neurodegeneration: current and future practices. Alz Res Ther. 2020;12(1):49.","journal-title":"Alz Res Ther"},{"issue":"1\u20132","key":"1921_CR121","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1155\/2009\/609839","volume":"21","author":"GD Rabinovici","year":"2009","unstructured":"Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis In Vivo. Behav Neurol. 2009;21(1\u20132):117\u201328.","journal-title":"Behav Neurol"},{"issue":"6","key":"1921_CR122","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.112.114785","volume":"54","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of<Superscript>11<\/Superscript>C-PiB and<Superscript>18<\/Superscript>F-AZD4694 (NAV4694) for \u03b2-amyloid imaging in aging and dementia. J Nucl Med. 2013;54(6):880\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"1921_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1921_CR124","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1002\/alz.13883","volume":"20","author":"M Shekari","year":"2024","unstructured":"Shekari M, V\u00e1llez Garc\u00eda D, Collij LE, Altomare D, Heeman F, Pemberton H, et al. Stress testing the Centiloid: precision and variability of PET quantification of amyloid pathology. Alzheimers Dement. 2024;20(8):5102\u201313.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1921_CR125","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"1921_CR126","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"5","key":"1921_CR127","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1002\/alz.13761","volume":"20","author":"A Bollack","year":"2024","unstructured":"Bollack A, Collij LE, Garc\u00eda DV, Shekari M, Altomare D, Payoux P, et al. Investigating reliable amyloid accumulation in Centiloids: results from the AMYPAD prognostic and natural history study. Alzheimers Dement. 2024;20(5):3429\u201341.","journal-title":"Alzheimers Dement"},{"key":"1921_CR128","doi-asserted-by":"crossref","unstructured":"Klein G, Delmar P, Kerchner GA, Hofmann C, Abi-Saab D, Davis A et al. Thirty-Six-Month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab. J Prev Alz Dis. 2020;8(1):3-6.","DOI":"10.14283\/jpad.2020.68"},{"issue":"2","key":"1921_CR129","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [<Superscript>11<\/Superscript>C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1921_CR130","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2967\/jnumed.112.113654","volume":"54","author":"BNM Van Berckel","year":"2013","unstructured":"Van Berckel BNM, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using<Superscript>11<\/Superscript>C-PiB: methodologic considerations. J Nucl Med. 2013;54(9):1570\u20136.","journal-title":"J Nucl Med"},{"issue":"5","key":"1921_CR131","doi-asserted-by":"publisher","first-page":"670","DOI":"10.2967\/jnumed.123.265766","volume":"65","author":"WJ Jagust","year":"2024","unstructured":"Jagust WJ, Mattay VS, Krainak DM, Wang S-J, Weidner LD, Hofling AA, et al. Quantitative brain amyloid PET. J Nucl Med. 2024;65(5):670\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"1921_CR132","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2967\/jnumed.124.268119","volume":"66","author":"LE Collij","year":"2024","unstructured":"Collij LE, Bischof GN, Altomare D, Bader I, Battle M, V\u00e1llez Garc\u00eda D, et al. Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study. J Nucl Med. 2024;66(1):110\u20136.","journal-title":"J Nucl Med"},{"issue":"6","key":"1921_CR133","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"1921_CR134","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s Disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"1921_CR135","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [<Superscript>18<\/Superscript>F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1921_CR136","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s00259-019-04297-5","volume":"46","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Savitcheva I, Chiotis K, Lilja J, Andersen P, Bogdanovic N, et al. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J Nucl Med Mol Imaging. 2019;46(6):1276\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1921_CR137","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/ph14020110","volume":"14","author":"C Jie","year":"2021","unstructured":"Jie C, Treyer V, Schibli R, Mu L. Tauvid\u2122: the first FDA-approved PET tracer for imaging Tau pathology in Alzheimer\u2019s disease. Pharmaceuticals. 2021;14(2):110.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1921_CR138","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2967\/jnumed.124.267539","volume":"66","author":"A Aliaga","year":"2025","unstructured":"Aliaga A, Therriault J, Quispialaya KM, Aliaga A, Hopewell R, Rahmouni N, et al. Comparison between brain and cerebellar autoradiography using [<Superscript>18<\/Superscript>F]flortaucipir, [<Superscript>18<\/Superscript>F]MK6240, and [<Superscript>18<\/Superscript>F]PI2620 in postmortem human brain tissue. J Nucl Med. 2025;66(1):123\u20139.","journal-title":"J Nucl Med"},{"key":"1921_CR139","unstructured":"AC Immune. AC Immune\u2019s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions. AC Immune. News Release. 2024 Aug 28. Available from: https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-pi-2620-tau-pet-diagnostic-phase-3-receives-fast"},{"key":"1921_CR140","unstructured":"Life Molecular Imaging. Life Molecular Imaging Receives FDA Fast Track Designation for [18F]PI-2620 in Tau PET Imaging Across Three Neurodegenerative Conditions. Life Molecular Imaging. 2024 Aug 28. Available from: https:\/\/life-mi.com\/life-molecular-imaging-receives-fda-fast-track-designation-for-18fpi-2620-in-tau-pet-imaging-across-three-neurodegenerative-conditions\/"},{"key":"1921_CR141","unstructured":"Lantheus. Lantheus Announces Alzheimer\u2019s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies. Lantheus. 2025 April 30. Available from: https:\/\/lantheusholdings.gcs-web.com\/news-releases\/news-release-details\/lantheus-announces-alzheimers-disease-radiodiagnostic-mk-6240"},{"issue":"1","key":"1921_CR142","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/alz.13355","volume":"20","author":"C Boccalini","year":"2024","unstructured":"Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti DE, Mu L, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimer\u2019s & Dementia. 2024;20(1):221\u201333.","journal-title":"Alzheimer's & Dementia"},{"issue":"Supplement 1","key":"1921_CR143","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2967\/jnumed.121.263196","volume":"63","author":"C Groot","year":"2022","unstructured":"Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET imaging in neurodegenerative disorders. J Nucl Med. 2022;63(Supplement 1):S20\u20136.","journal-title":"J Nucl Med"},{"issue":"5","key":"1921_CR144","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, Lockhart SN, Schonhaut DR, O\u2019Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of Tau deposition in the aging human brain. Neuron. 2016;89(5):971\u201382.","journal-title":"Neuron"},{"issue":"35","key":"1921_CR145","doi-asserted-by":"publisher","first-page":"27302","DOI":"10.1074\/jbc.M110.145318","volume":"285","author":"S Wegmann","year":"2010","unstructured":"Wegmann S, Jung YJ, Chinnathambi S, Mandelkow E-M, Mandelkow E, Muller DJ. Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. J Biol Chem. 2010;285(35):27302\u201313.","journal-title":"J Biol Chem"},{"issue":"1","key":"1921_CR146","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jalz.2018.05.006","volume":"15","author":"J Cummings","year":"2019","unstructured":"Cummings J. The National Institute on Aging\u2014Alzheimer\u2019s association framework on Alzheimer\u2019s disease: application to clinical trials. Alzheimers Dement. 2019;15(1):172\u20138.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1921_CR147","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78(8):961.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1921_CR148","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/ana.27008","volume":"96","author":"DN Soleimani-Meigooni","year":"2024","unstructured":"Soleimani-Meigooni DN, Smith R, Provost K, Lesman\u2010Segev OH, Allen IE, Chen MK, et al. Head\u2010to\u2010head comparison of tau and amyloid positron emission tomography visual reads for differential diagnosis of neurodegenerative disorders: an international, multicenter study. Ann Neurol. 2024;96(3):476\u201387.","journal-title":"Ann Neurol"},{"issue":"3","key":"1921_CR149","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-022-05999-z","volume":"50","author":"J Wang","year":"2023","unstructured":"Wang J, Jin C, Zhou J, Zhou R, Tian M, Lee HJ, et al. PET molecular imaging for pathophysiological visualization in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2023;50(3):765\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1921_CR150","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2967\/jnumed.120.254961","volume":"63","author":"A Gogola","year":"2022","unstructured":"Gogola A, Minhas DS, Villemagne VL, Cohen AD, Mountz JM, Pascoal TA, et al. Direct comparison of the tau PET tracers<Superscript>18<\/Superscript>F-Flortaucipir and<Superscript>18<\/Superscript>F-MK-6240 in human subjects. J Nucl Med. 2022;63(1):108\u201316.","journal-title":"J Nucl Med"},{"issue":"6","key":"1921_CR151","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/brain\/awu093","volume":"137","author":"W Jagust","year":"2014","unstructured":"Jagust W. Time for tau. Brain. 2014;137(6):1570\u20131.","journal-title":"Brain"},{"issue":"9","key":"1921_CR152","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2967\/jnumed.123.267273","volume":"65","author":"RK Gebre","year":"2024","unstructured":"Gebre RK, Rial AM, Raghavan S, Wiste HJ, Heeman F, Costoya-S\u00e1nchez A, et al. Advancing tau PET quantification in Alzheimer disease with machine learning: introducing THETA, a novel tau summary measure. J Nucl Med. 2024;65(9):1473\u201380.","journal-title":"J Nucl Med"},{"issue":"3","key":"1921_CR153","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12454","volume":"15","author":"VL Villemagne","year":"2023","unstructured":"Villemagne VL, Leuzy A, Bohorquez SS, Bullich S, Shimada H, Rowe CC, et al. CenTauR: toward a universal scale and masks for standardizing tau imaging studies. Alz & Dem Diag Ass & Dis Mo. 2023;15(3):e12454.","journal-title":"Alz & Dem Diag Ass & Dis Mo"},{"issue":"Suppl 8","key":"1921_CR154","first-page":"e095751","volume":"20","author":"A Moscoso","year":"2025","unstructured":"Moscoso A, van Essen M, Mainta I, Camacho V, Rodr\u00edguez-Fonseca O, Silva\u2010Rodr\u00edguez J, Perissinotti A, Franzmeier N, Grothe MJ, Frisoni GB, Garibotto V, Sch\u00f6ll M. Concordance between visual interpretation of [18F]flortaucipir PET images and the universal centaur scale. Alzheimers Dement. 2025;20(Suppl 8):e095751.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1921_CR155","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jama.2025.7817","volume":"334","author":"A Moscoso","year":"2025","unstructured":"Moscoso A, Heeman F, Raghavan S, Costoya-S\u00e1nchez A, van Essen M, Mainta I, et al. Frequency and clinical outcomes associated with tau positron emission tomography positivity. JAMA. 2025;334(3):229\u201342.","journal-title":"JAMA"},{"issue":"1","key":"1921_CR156","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/nimg.2002.1208","volume":"17","author":"K Herholz","year":"2002","unstructured":"Herholz K, Salmon E, Perani D, Baron J-C, Holthoff V, Fr\u00f6lich L, et al. Discrimination between alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17(1):302\u201316.","journal-title":"Neuroimage"},{"issue":"4","key":"1921_CR157","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","volume":"32","author":"L Mosconi","year":"2005","unstructured":"Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32(4):486\u2013510.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1921_CR158","doi-asserted-by":"publisher","first-page":"1151820","DOI":"10.3389\/fnins.2023.1151820","volume":"17","author":"Z Yang","year":"2023","unstructured":"Yang Z, Cummings JL, Kinney JW, Cordes D. The alzheimer\u2019s disease neuroimaging Initiative. Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients. Front Neurosci. 2023;17:1151820.","journal-title":"Front Neurosci"},{"issue":"4","key":"1921_CR159","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40336-013-0026-y","volume":"1","author":"L Mosconi","year":"2013","unstructured":"Mosconi L. Glucose metabolism in normal aging and alzheimer\u2019s disease: methodological and physiological considerations for PET studies. Clin Transl Imaging. 2013;1(4):217\u201333.","journal-title":"Clin Transl Imaging"},{"issue":"6","key":"1921_CR160","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1921_CR161","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2967\/jnumed.119.230797","volume":"61","author":"G Blazhenets","year":"2020","unstructured":"Blazhenets G, Ma Y, S\u00f6rensen A, Schiller F, R\u00fccker G, Eidelberg D, et al. Predictive value of18 F-Florbetapir and18 F-FDG PET for conversion from mild cognitive impairment to Alzheimer dementia. J Nucl Med. 2020;61(4):597\u2013603.","journal-title":"J Nucl Med"},{"issue":"11","key":"1921_CR162","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Ch\u00e9telat","year":"2020","unstructured":"Ch\u00e9telat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19(11):951\u201362.","journal-title":"Lancet Neurol"},{"key":"1921_CR163","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.exger.2018.01.002","volume":"107","author":"AD Henriques","year":"2018","unstructured":"Henriques AD, Benedet AL, Camargos EF, Rosa-Neto P, N\u00f3brega OT. Fluid and imaging biomarkers for Alzheimer\u2019s disease: where we stand and where to head to. Exp Gerontol. 2018;107:169\u201377.","journal-title":"Exp Gerontol"},{"issue":"1","key":"1921_CR164","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1474-4422(02)00002-9","volume":"1","author":"P Scheltens","year":"2002","unstructured":"Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002;1(1):13\u201321.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1921_CR165","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2217\/17520363.1.1.79","volume":"1","author":"J Barnes","year":"2007","unstructured":"Barnes J, Foster J, Fox NC. Structural magnetic resonance imaging-derived biomarkers for Alzheimer\u2019s disease. Biomark Med. 2007;1(1):79\u201392.","journal-title":"Biomark Med"},{"key":"1921_CR166","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejrad.2017.07.014","volume":"94","author":"L Rice","year":"2017","unstructured":"Rice L, Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer\u2019s disease\u2014a systematic review. Eur J Radiol. 2017;94:16\u201324.","journal-title":"Eur J Radiol"},{"issue":"11","key":"1921_CR167","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","volume":"58","author":"H Barthel","year":"2017","unstructured":"Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58(11):1711\u20137.","journal-title":"J Nucl Med"},{"issue":"8","key":"1921_CR168","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg P-G, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry. 2019;24(8):1112\u201334.","journal-title":"Mol Psychiatry"},{"issue":"12","key":"1921_CR169","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","volume":"73","author":"M Boccardi","year":"2016","unstructured":"Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18 F]-florbetapir (INDIA-FBP) study. JAMA Neurol. 2016;73(12):1417.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1921_CR170","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00259-020-04969-7","volume":"48","author":"G Perini","year":"2021","unstructured":"Perini G, Rodriguez-Vieitez E, Kadir A, Sala A, Savitcheva I, Nordberg A. Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. Eur J Nucl Med Mol Imaging. 2021;48(2):612\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1921_CR171","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Sch\u00f6ll M, Strandberg O, et al. Discriminative accuracy of [<Superscript>18<\/Superscript>F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151.","journal-title":"JAMA"},{"issue":"4","key":"1921_CR172","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","volume":"20","author":"J Therriault","year":"2024","unstructured":"Therriault J, Schindler SE, Salvad\u00f3 G, Pascoal TA, Benedet AL, Ashton NJ, et al. Biomarker-based staging of alzheimer disease: rationale and clinical applications. Nat Rev Neurol. 2024;20(4):232\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"19","key":"1921_CR173","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924.","journal-title":"JAMA"},{"issue":"1","key":"1921_CR174","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-023-01209-6","volume":"15","author":"A Snellman","year":"2023","unstructured":"Snellman A, Ekblad LL, Tuisku J, Koivum\u00e4ki M, Ashton NJ, Lantero-Rodriguez J, et al. APOE \u03b54 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Alz Res Ther. 2023;15(1):71.","journal-title":"Alz Res Ther"},{"issue":"23","key":"1921_CR175","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1001\/jama.2019.7437","volume":"321","author":"CR Jack","year":"2019","unstructured":"Jack CR, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316.","journal-title":"JAMA"},{"issue":"10","key":"1921_CR176","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00259-013-2478-8","volume":"40","author":"A Br\u00fcck","year":"2013","unstructured":"Br\u00fcck A, Virta JR, Koivunen J, Koikkalainen J, Scheinin NM, Helenius H, et al. [11\u00a0C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2013;40(10):1567\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1921_CR177","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg YAL, Lemstra AW, Van Der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9(4):414\u201321.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1921_CR178","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/archneur.63.5.693","volume":"63","author":"LG Apostolova","year":"2006","unstructured":"Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006;63(5):693.","journal-title":"Arch Neurol"},{"issue":"7","key":"1921_CR179","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.neurobiolaging.2008.08.008","volume":"31","author":"LG Apostolova","year":"2010","unstructured":"Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, et al. Subregional hippocampal atrophy predicts Alzheimer\u2019s dementia in the cognitively normal. Neurobiol Aging. 2010;31(7):1077\u201388.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"1921_CR180","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1212\/01.wnl.0000256697.20968.d7","volume":"68","author":"DP Devanand","year":"2007","unstructured":"Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology. 2007;68(11):828\u201336.","journal-title":"Neurology"},{"key":"1921_CR181","doi-asserted-by":"publisher","unstructured":"Lombardi G, Crescioli G, Cavedo E, Lucenteforte E, Casazza G, Bellatorre A-G et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer\u2019s disease in people with mild cognitive impairment. Cochrane database of systematic Reviews.;(3):. Epub ahead of print 2 March 2020. https:\/\/doi.org\/10.1002\/14651858.CD009628.pub2.","DOI":"10.1002\/14651858.CD009628.pub2"},{"key":"1921_CR182","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","volume":"52","author":"K Chiotis","year":"2017","unstructured":"Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214\u201327.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1921_CR183","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J, et al. Defining a centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48(1):302\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1921_CR184","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3233\/JAD-170158","volume":"59","author":"L Iaccarino","year":"2017","unstructured":"Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, Cerami C, et al. A cross-validation of FDG- and Amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to dementia due to Alzheimer\u2019s disease in a clinical setting. JAD. 2017;59(2):603\u201314.","journal-title":"JAD"},{"issue":"4","key":"1921_CR185","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ana.23650","volume":"72","author":"SM Landau","year":"2012","unstructured":"Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578\u201386.","journal-title":"Ann Neurol"},{"issue":"1","key":"1921_CR186","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40035-018-0114-z","volume":"7","author":"HR Ma","year":"2018","unstructured":"Ma HR, Sheng LQ, Pan PL, Wang GD, Luo R, Shi HC, et al. Cerebral glucose metabolic prediction from amnestic mild cognitive impairment to Alzheimer\u2019s dementia: a meta-analysis. Transl Neurodegener. 2018;7(1):9.","journal-title":"Transl Neurodegener"},{"key":"1921_CR187","doi-asserted-by":"crossref","unstructured":"Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. 18 F-FDG PET for the early diagnosis of alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Reviews. 2015;(1):CD010632.","DOI":"10.1002\/14651858.CD010632.pub2"},{"key":"1921_CR188","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nicl.2018.01.019","volume":"18","author":"SP Caminiti","year":"2018","unstructured":"Caminiti SP, Ballarini T, Sala A, Cerami C, Presotto L, Santangelo R, et al. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. NeuroImage: Clinical. 2018;18:167\u201377.","journal-title":"NeuroImage: Clinical"},{"key":"1921_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fninf.2018.00035","volume":"12","author":"M Liu","year":"2018","unstructured":"Liu M, Cheng D, Yan W, Alzheimer\u2019s Disease Neuroimaging Initiative. Classification of Alzheimer\u2019s Disease by combination of convolutional and recurrent neural networks using FDG-PET images. Front Neuroinform. 2018;12:35.","journal-title":"Front Neuroinform"},{"issue":"8","key":"1921_CR190","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jalz.2019.02.007","volume":"15","author":"H Li","year":"2019","unstructured":"Li H, Habes M, Wolk DA, Fan Y. Alzheimer\u2019s disease neuroimaging initiative and the Australian imaging biomarkers and lifestyle study of Aging. A deep learning model for early prediction of Alzheimer\u2019s disease dementia based on hippocampal magnetic resonance imaging data. Alzheimers Dement. 2019;15(8):1059\u201370.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1921_CR191","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac193","volume":"4","author":"M Bilgel","year":"2022","unstructured":"Bilgel M, Wong DF, Moghekar AR, Ferrucci L, Resnick SM, the Alzheimer\u2019s Disease Neuroimaging Initiative. Causal links among amyloid, tau, and neurodegeneration. Brain Commun. 2022;4(4):fcac193.","journal-title":"Brain Commun"},{"issue":"1","key":"1921_CR192","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12(1):19.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1921_CR193","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(5):1551\u201367.","journal-title":"Brain"},{"issue":"8","key":"1921_CR194","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Van Der Kant R, Hansson O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21(8):726\u201334.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1921_CR195","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","volume":"2","author":"J Therriault","year":"2022","unstructured":"Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, et al. Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat Aging. 2022;2(6):526\u201335.","journal-title":"Nat Aging"},{"issue":"2","key":"1921_CR196","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41380-024-02672-9","volume":"30","author":"K Ioannou","year":"2024","unstructured":"Ioannou K, Bucci M, Tzortzakakis A, Savitcheva I, Nordberg A, Chiotis K, et al. Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer\u2019s disease compared to comorbid cases; proof of concept in the ADNI study. Mol Psychiatry. 2024;30(2):587\u201399.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"1921_CR197","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"the Alzheimer\u2019s Disease Neuroimaging Initiative, Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, et al. Four distinct trajectories of Tau deposition identified in alzheimer\u2019s disease. Nat Med. 2021;27(5):871\u201381.","journal-title":"Nat Med"},{"issue":"1","key":"1921_CR198","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/brain\/awz378","volume":"143","author":"TJ Betthauser","year":"2020","unstructured":"Betthauser TJ, Koscik RL, Jonaitis EM, Allison SL, Cody KA, Erickson CM, et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain. 2020;143(1):320\u201335.","journal-title":"Brain"},{"issue":"5054","key":"1921_CR199","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135.","journal-title":"Science"},{"issue":"s3","key":"1921_CR200","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3233\/JAD-2006-9S317","volume":"9","author":"J Hardy","year":"2006","unstructured":"Hardy J. Alzheimer\u2019s disease: the amyloid cascade hypothesis: an update and reappraisal. JAD. 2006;9(s3):151\u20133.","journal-title":"JAD"},{"issue":"1","key":"1921_CR201","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12312","volume":"8","author":"AM Wessels","year":"2022","unstructured":"Wessels AM, Rentz DM, Case M, Lauzon S, Sims JR. Integrated Alzheimer\u2019s disease rating scale: clinically meaningful change estimates. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2022;8(1):e12312.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"1921_CR202","doi-asserted-by":"publisher","unstructured":"Chin E, Jaqua E, Safaeipour M, Ladue T. Conventional versus new treatment: comparing the effects of acetylcholinesterase inhibitors and N-Methyl-D-Aspartate receptor antagonist with Aducanumab. Cureus.;14(11):. Epub ahead of print 3 November 2022. https:\/\/doi.org\/10.7759\/cureus.31065","DOI":"10.7759\/cureus.31065"},{"issue":"2","key":"1921_CR203","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9(2):211\u201320.","journal-title":"J Prev Alzheimers Dis"},{"key":"1921_CR204","doi-asserted-by":"crossref","unstructured":"Bash S, Tanenbaum LN. Sep 12,. (2023). Alzheimer Disease Imaging in the Era of Anti-Amyloid Treatment. Appl Radiol. 2023; 52(5):16\u201323.","DOI":"10.37549\/AR2918"},{"issue":"8","key":"1921_CR205","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/RLU.0000000000004710","volume":"48","author":"PF H\u00f8ilund-Carlsen","year":"2023","unstructured":"H\u00f8ilund-Carlsen PF, Revheim M-E, Alavi A, Barrio JR. FDG PET (and MRI) for monitoring immunotherapy in Alzheimer disease. Clin Nucl Med. 2023;48(8):689\u201391.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1921_CR206","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40658-019-0258-7","volume":"6","author":"FJ L\u00f3pez-Gonz\u00e1lez","year":"2019","unstructured":"for the Alzheimer\u2019s Disease Neuroimaging Initiative, L\u00f3pez-Gonz\u00e1lez FJ, Moscoso A, Efthimiou N, Fern\u00e1ndez-Ferreiro A, Pi\u00f1eiro-Fiel M, et al. Spill-in counts in the quantification of 18F-florbetapir on A\u03b2-negative subjects: the effect of including white matter in the reference region. EJNMMI Phys. 2019;6(1):27.","journal-title":"EJNMMI Phys"},{"issue":"2","key":"1921_CR207","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00259-019-04564-5","volume":"47","author":"A Alavi","year":"2020","unstructured":"Alavi A, Barrio JR, Werner TJ, Khosravi M, Newberg A, H\u00f8ilund-Carlsen PF. Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer\u2019s disease: why it is time to abandon the approach. Eur J Nucl Med Mol Imaging. 2020;47(2):225\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1921_CR208","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3233\/JAD-220841","volume":"90","author":"PF H\u00f8ilund-Carlsen","year":"2022","unstructured":"H\u00f8ilund-Carlsen PF, Revheim M-E, Alavi A, Satyamurthy N, Barrio JR. Amyloid PET: a questionable single primary surrogate efficacy measure on Alzheimer immunotherapy trials. JAD. 2022;90(4):1395\u20139.","journal-title":"JAD"},{"issue":"3","key":"1921_CR209","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1620\/tjem.234.175","volume":"234","author":"A Arai","year":"2014","unstructured":"Arai A, Kaneta T, Okamura N, Tashiro M, Iwata R, Takanami K, et al. Pitfalls of voxel-based amyloid PET analyses for diagnosis of Alzheimer\u2019s disease: artifacts due to non-specific uptake in the white matter and the skull. Tohoku J Exp Med. 2014;234(3):175\u201381.","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"1921_CR210","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/s00259-021-05493-y","volume":"49","author":"A Moscoso","year":"2022","unstructured":"Moscoso A, Silva-Rodr\u00edguez J, Aldrey JM, Cort\u00e9s J, P\u00edas-Peleteiro JM, Ruibal \u00c1, et al. 18F-florbetapir PET as a marker of Myelin integrity across the Alzheimer\u2019s disease spectrum. Eur J Nucl Med Mol Imaging. 2022;49(4):1242\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1921_CR211","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.bcp.2013.11.009","volume":"88","author":"H Hampel","year":"2014","unstructured":"Hampel H, Lista S, Teipel SJ, Garaci F, Nistic\u00f2 R, Blennow K, et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer\u2019s disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014;88(4):426\u201349.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1921_CR212","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3233\/JAD-190220","volume":"70","author":"M Khosravi","year":"2019","unstructured":"Khosravi M, Peter J, Wintering NA, Serruya M, Shamchi SP, Werner TJ, et al. 18F-FDG is a superior indicator of cognitive performance compared to 18F-Florbetapir in Alzheimer\u2019s disease and mild cognitive impairment evaluation: a global quantitative analysis. J Alzheimers Dis. 2019;70(4):1197\u2013207.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"1921_CR213","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1474-4422(24)00335-1","volume":"23","author":"CRS Belder","year":"2024","unstructured":"Belder CRS, Boche D, Nicoll JAR, Jaunmuktane Z, Zetterberg H, Schott JM, et al. Brain volume change following anti-amyloid \u03b2 immunotherapy for Alzheimer\u2019s disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol. 2024;23(10):1025\u201334.","journal-title":"Lancet Neurol"},{"issue":"20","key":"1921_CR214","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1212\/WNL.0000000000207268","volume":"100","author":"F Barkhof","year":"2023","unstructured":"Barkhof F, Knopman DS. Brain shrinkage in anti\u2013\u03b2-amyloid Alzheimer trials: neurodegeneration or pseudoatrophy? Neurology. 2023;100(20):941\u20132.","journal-title":"Neurology"},{"issue":"2","key":"1921_CR215","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alz Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alz Dis"},{"issue":"2","key":"1921_CR216","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.neuroimage.2010.02.064","volume":"51","author":"K Chen","year":"2010","unstructured":"Chen K, Langbaum JBS, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve-month metabolic declines in probable Alzheimer\u2019s disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer\u2019s disease neuroimaging initiative. NeuroImage. 2010;51(2):654\u201364.","journal-title":"NeuroImage"},{"issue":"4","key":"1921_CR217","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jalz.2018.03.002","volume":"14","author":"DS Knopman","year":"2018","unstructured":"Knopman DS, Haeberlein SB, Carrillo MC, Hendrix JA, Kerchner G, Margolin R, et al. The National Institute on aging and the alzheimer\u2019s association research framework for Alzheimer\u2019s disease: perspectives from the research roundtable. Alzheimers Dement. 2018;14(4):563\u201375.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1921_CR218","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2967\/jnumed.122.265309","volume":"65","author":"EA Bartlett","year":"2024","unstructured":"Bartlett EA, Lesanpezeshki M, Anishchenko S, Shkolnik I, Ogden RT, Mann JJ, et al. Dynamic human brain imaging with a portable PET camera: comparison to a standard scanner. J Nucl Med. 2024;65(2):320\u20136.","journal-title":"J Nucl Med"},{"key":"1921_CR219","doi-asserted-by":"publisher","first-page":"1005731","DOI":"10.3389\/fnagi.2022.1005731","volume":"14","author":"M Perovnik","year":"2022","unstructured":"Perovnik M, Vo A, Nguyen N, Jam\u0161ek J, Rus T, Tang CC, et al. Automated differential diagnosis of dementia syndromes using FDG PET and machine learning. Front Aging Neurosci. 2022;14:1005731.","journal-title":"Front Aging Neurosci"},{"key":"1921_CR220","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fpsyt.2019.00953","volume":"10","author":"S Frenzel","year":"2020","unstructured":"Frenzel S, Wittfeld K, Habes M, Klinger-K\u00f6nig J, B\u00fclow R, V\u00f6lzke H, et al. A biomarker for Alzheimer\u2019s disease based on patterns of regional brain atrophy. Front Psychiatry. 2020;10:953.","journal-title":"Front Psychiatry"},{"issue":"12","key":"1921_CR221","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/alz.12356","volume":"17","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Hansson O. Towards clinical application of Tau PET tracers for diagnosing dementia due to Alzheimer\u2019s disease. Alzheimers Dement. 2021;17(12):1998\u20132008.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1921_CR222","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.2967\/jnumed.118.224113","volume":"60","author":"SL Baker","year":"2019","unstructured":"Baker SL, Harrison TM, Maass A, La Joie R, Jagust WJ. Effect of off-target binding on<Superscript>18<\/Superscript>F-flortaucipir variability in healthy controls across the life span. J Nucl Med. 2019;60(10):1444\u201351.","journal-title":"J Nucl Med"},{"key":"1921_CR223","doi-asserted-by":"publisher","first-page":"1380561","DOI":"10.3389\/fnagi.2024.1380561","volume":"16","author":"MS Bavarsad","year":"2024","unstructured":"Bavarsad MS, Grinberg LT. SV2A PET imaging in human neurodegenerative diseases. Front Aging Neurosci. 2024;16:1380561.","journal-title":"Front Aging Neurosci"},{"issue":"10312","key":"1921_CR224","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(21)01824-9","volume":"398","author":"I Kickbusch","year":"2021","unstructured":"Kickbusch I, Piselli D, Agrawal A, Balicer R, Banner O, Adelhardt M, et al. The Lancet and Financial Times Commission on governing health futures 2030: growing up in a digital world. Lancet. 2021;398(10312):1727\u201376.","journal-title":"Lancet"},{"issue":"1","key":"1921_CR225","doi-asserted-by":"publisher","DOI":"10.1136\/bmjhci-2023-100914","volume":"31","author":"AK Macias Alonso","year":"2024","unstructured":"Macias Alonso AK, Hirt J, Woelfle T, Janiaud P, Hemkens LG. Definitions of digital biomarkers: a systematic mapping of the biomedical literature. BMJ Health Care Inform. 2024;31(1):e100914.","journal-title":"BMJ Health Care Inform"},{"issue":"1","key":"1921_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01583-5","volume":"8","author":"SE Polk","year":"2025","unstructured":"Polk SE, \u00d6hman F, Hassenstab J, K\u00f6nig A, Papp KV, Sch\u00f6ll M, et al. A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer\u2019s disease. NPJ Digit Med. 2025;8(1):266.","journal-title":"NPJ Digit Med"},{"issue":"2","key":"1921_CR227","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000502000","volume":"3","author":"LM Babrak","year":"2019","unstructured":"Babrak LM, Menetski J, Rebhan M, Nisato G, Zinggeler M, Brasier N, et al. Traditional and digital biomarkers: two worlds apart? Digit Biomark. 2019;3(2):92\u2013102.","journal-title":"Digit Biomark"},{"issue":"1","key":"1921_CR228","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01217-2","volume":"7","author":"Y Sun","year":"2024","unstructured":"Sun Y, Wang Z, Liang Y, Hao C, Shi C. Digital biomarkers for precision diagnosis and monitoring in Parkinson\u2019s disease. NPJ Digit Med. 2024;7(1):218.","journal-title":"NPJ Digit Med"},{"key":"1921_CR229","doi-asserted-by":"crossref","unstructured":"Alexopoulou Z-S, K\u00f6hler S, Mallick E, Tr\u00f6ger J, Linz N, Spruth E et al. Speech-based digital cognitive assessments for detection of mild cognitive impairment: validation against paper-based neurocognitive assessment scores. J Alzheimers Dis. 2025;13872877251343296.","DOI":"10.1177\/13872877251343296"},{"issue":"4","key":"1921_CR230","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/alz.13716","volume":"20","author":"G \u010cepukaityt\u0117","year":"2024","unstructured":"\u010cepukaityt\u0117 G, Newton C, Chan D. Early detection of diseases causing dementia using digital navigation and gait measures: a systematic review of evidence. Alzheimers Dement. 2024;20(4):3054\u201373.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1921_CR231","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3233\/JAD-170541","volume":"60","author":"R Mc Ardle","year":"2017","unstructured":"Mc Ardle R, Morris R, Wilson J, Galna B, Thomas AJ, Rochester L. What can quantitative gait analysis tell us about dementia and its subtypes? A structured review. J Alzheimers Dis. 2017;60(4):1295\u2013312.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1921_CR232","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1007\/s00415-022-11544-7","volume":"270","author":"E Sarasso","year":"2023","unstructured":"Sarasso E, Filippi M, Agosta F. Clinical and MRI features of gait and balance disorders in neurodegenerative diseases. J Neurol. 2023;270(3):1798\u2013807.","journal-title":"J Neurol"},{"key":"1921_CR233","doi-asserted-by":"crossref","unstructured":"De Cock A-M, Fransen E, Perkisas S, Verhoeven V, Beauchet O, Vandewoude M et al. Comprehensive quantitative spatiotemporal gait analysis identifies gait characteristics for early dementia subtyping in community dwelling older adults. Front Neurol. 2019;10313.","DOI":"10.3389\/fneur.2019.00313"},{"issue":"2","key":"1921_CR234","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3233\/JPD-202098","volume":"11","author":"SL Amundsen-Huffmaster","year":"2021","unstructured":"Amundsen-Huffmaster SL, Petrucci MN, Linn-Evans ME, Chung JW, Howell MJ, Videnovic A, et al. REM sleep without atonia and gait impairment in people with mild-to-moderate parkinson\u2019s disease. JPD. 2021;11(2):767\u201378.","journal-title":"JPD"},{"issue":"4","key":"1921_CR235","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/gerona\/glr177","volume":"67A","author":"G Abellan Van Kan","year":"2012","unstructured":"Abellan Van Kan G, Rolland Y, Gillette-Guyonnet S, Gardette V, Annweiler C, Beauchet O, et al. Gait speed, body composition, and dementia. The EPIDOS-Toulouse cohort. J Gerontol A Biol Sci Med Sci. 2012;67A(4):425\u201332.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"1921_CR236","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1212\/WNL.0000000000002235","volume":"86","author":"N Del Campo","year":"2016","unstructured":"Del Campo N, Payoux P, Djilali A, Delrieu J, Hoogendijk EO, Rolland Y, et al. Relationship of regional brain \u03b2-amyloid to gait speed. Neurology. 2016;86(1):36\u201343.","journal-title":"Neurology"},{"issue":"4","key":"1921_CR237","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/ggi.12291","volume":"15","author":"T Doi","year":"2015","unstructured":"Doi T, Shimada H, Makizako H, Tsutsumimoto K, Uemura K, Suzuki T. Apolipoprotein E genotype and physical function among older people with mild cognitive impairment. Geriatr Gerontol Int. 2015;15(4):422\u20137.","journal-title":"Geriatr Gerontol Int"},{"issue":"3","key":"1921_CR238","doi-asserted-by":"publisher","first-page":"291","DOI":"10.14283\/jfa.2022.17","volume":"11","author":"ME Jacob","year":"2022","unstructured":"Jacob ME, O\u2019Donnell A, Samra J, Gonzales MM, Satizabal C, Pase MP, et al. Grip Strength, gait speed and plasma markers of neurodegeneration in asymptomatic middle-aged and older adults. J Frailty Aging. 2022;11(3):291\u20138.","journal-title":"J Frailty Aging"},{"issue":"8","key":"1921_CR239","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1080\/00207454.2021.2019034","volume":"133","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Chung EJ, Ji K-H, Kang M-R, Hong JY, Lee S, et al. Correlations with REM sleep behavior disorder severity in isolated rapid eye movement sleep behavior disorders patients. Int J Neurosci. 2023;133(8):918\u201324.","journal-title":"Int J Neurosci"},{"issue":"4","key":"1921_CR240","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3233\/JAD-160229","volume":"53","author":"EC Camargo","year":"2016","unstructured":"Camargo EC, Weinstein G, Beiser AS, Tan ZS, DeCarli C, Kelly-Hayes M, et al. Association of physical function with clinical and subclinical brain disease: the Framingham Offspring Study. J Alzheimers Dis. 2016;53(4):1597\u2013608.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"1921_CR241","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jamda.2019.01.134","volume":"20","author":"T Doi","year":"2019","unstructured":"Doi T, Tsutsumimoto K, Nakakubo S, Kim M-J, Kurita S, Shimada H. Rethinking the relationship between spatiotemporal gait variables and dementia: a prospective study. J Am Med Dir Assoc. 2019;20(7):899\u2013903.","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"1921_CR242","first-page":"655","volume":"72","author":"J Dumurgier","year":"2016","unstructured":"Dumurgier J, Artaud F, Touraine C, Rouaud O, Tavernier B, Dufouil C, et al. Gait speed and decline in gait speed as predictors of incident dementia. J Gerontol Biol Sci Med Sci. 2016;72(5):655\u201361.","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"9","key":"1921_CR243","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/mds.27780","volume":"34","author":"KA Ehgoetz Martens","year":"2019","unstructured":"Ehgoetz Martens KA, Matar E, Hall JM, Phillips J, Szeto JYY, Gouelle A, et al. Subtle gait and balance impairments occur in idiopathic rapid eye movement sleep behavior disorder. Mov Disord. 2019;34(9):1374\u201380.","journal-title":"Mov Disord"},{"issue":"11","key":"1921_CR244","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.26665","volume":"31","author":"L Alibiglou","year":"2016","unstructured":"Alibiglou L, Videnovic A, Planetta PJ, Vaillancourt DE, MacKinnon CD. Subliminal gait initiation deficits in rapid eye movement sleep behavior disorder: a harbinger of freezing of gait? J Mov Disord. 2016;31(11):1711\u20139.","journal-title":"J Mov Disord"},{"issue":"6","key":"1921_CR245","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/gerona\/glz160","volume":"75","author":"AS Buchman","year":"2020","unstructured":"Buchman AS, Dawe RJ, Leurgans SE, Curran TA, Truty T, Yu L, et al. Different combinations of mobility metrics derived from a wearable sensor are associated with distinct health outcomes in older adults. J Gerontol A Biol Sci Med Sci. 2020;75(6):1176\u201383.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1921_CR246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gaitpost.2016.08.009","volume":"50","author":"NE Fritz","year":"2016","unstructured":"Fritz NE, Kegelmeyer DA, Kloos AD, Linder S, Park A, Kataki M, et al. Motor performance differentiates individuals with lewy body dementia, parkinson\u2019s and alzheimer\u2019s disease. Gait Posture. 2016;50:1\u20137.","journal-title":"Gait Posture"},{"issue":"7","key":"1921_CR247","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1002\/alz.13919","volume":"20","author":"D Berron","year":"2024","unstructured":"Berron D, Olsson E, Andersson F, Janelidze S, Tideman P, D\u00fczel E, et al. Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(7):4775\u201391.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1921_CR248","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1017\/S135561772200042X","volume":"29","author":"J Nicosia","year":"2023","unstructured":"Nicosia J, Aschenbrenner AJ, Balota DA, Sliwinski MJ, Tahan M, Adams S, et al. Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer\u2019s disease. J Int Neuropsychol Soc. 2023;29(5):459\u201371.","journal-title":"J Int Neuropsychol Soc"},{"issue":"1","key":"1921_CR249","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12243","volume":"13","author":"KV Papp","year":"2021","unstructured":"Papp KV, Samaroo A, Chou H, Buckley R, Schneider OR, Hsieh S, et al. Unsupervised mobile cognitive testing for use in preclinical Alzheimer\u2019s disease. Alz Dem Diagn Assess Dis Monit. 2021;13(1):e12243.","journal-title":"Alz Dem Diagn Assess Dis Monit"},{"issue":"1","key":"1921_CR250","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00978-6","volume":"6","author":"M Muurling","year":"2023","unstructured":"Muurling M, De Boer C, Vairavan S, Harms RL, Chadha AS, Tarnanas I, et al. Augmented reality versus standard tests to assess cognition and function in early Alzheimer\u2019s disease. NPJ Digit Med. 2023;6(1):234.","journal-title":"NPJ Digit Med"},{"issue":"8","key":"1921_CR251","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/13803395.2021.2009447","volume":"43","author":"H Wilks","year":"2021","unstructured":"Wilks H, Aschenbrenner AJ, Gordon BA, Balota DA, Fagan AM, Musiek E, et al. Sharper in the morning: cognitive time of day effects revealed with high-frequency smartphone testing. J Clin Exp Neuropsychol. 2021;43(8):825\u201337.","journal-title":"J Clin Exp Neuropsychol"},{"issue":"4","key":"1921_CR252","volume":"15","author":"LI Thompson","year":"2023","unstructured":"Thompson LI, Kunicki ZJ, Emrani S, Strenger J, De Vito AN, Britton KJ, et al. Remote and in-clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2023;15(4):e12500.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"2","key":"1921_CR253","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S1355617723000322","volume":"30","author":"NH Stricker","year":"2024","unstructured":"Stricker NH, Stricker JL, Frank RD, Fan WZ, Christianson TJ, Patel JS, et al. Stricker learning span criterion validity: a remote self-administered multi-device compatible digital word list memory measure shows similar ability to differentiate amyloid and Tau PET-defined biomarker groups as in-person auditory verbal learning test. J Int Neuropsychol Soc. 2024;30(2):138\u201351.","journal-title":"J Int Neuropsychol Soc"},{"issue":"1","key":"1921_CR254","volume":"12","author":"A Samaroo","year":"2020","unstructured":"Samaroo A, Amariglio RE, Burnham S, Sparks P, Properzi M, Schultz AP, et al. Diminished learning over repeated exposures (LORE) in preclinical Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2020;12(1):e12132.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"18","key":"1921_CR255","doi-asserted-by":"publisher","first-page":"e2577","DOI":"10.1212\/WNL.0000000000010728","volume":"95","author":"YY Lim","year":"2020","unstructured":"Lim YY, Baker JE, Bruns L, Mills A, Fowler C, Fripp J, et al. Association of deficits in short-term learning and A\u03b2 and hippocampal volume in cognitively normal adults. Neurology. 2020;95(18):e2577\u201385.","journal-title":"Neurology"},{"issue":"5","key":"1921_CR256","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.14283\/jpad.2024.99","volume":"11","author":"EA Boots","year":"2024","unstructured":"Boots EA, Frank RD, Fan WZ, Christianson TJ, Kremers WK, Stricker JL, et al. Continuous associations between remote self-administered cognitive measures and imaging biomarkers of Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2024;11(5):1467\u201379.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1921_CR257","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12217","volume":"13","author":"F \u00d6hman","year":"2021","unstructured":"\u00d6hman F, Hassenstab J, Berron D, Sch\u00f6ll M, Papp KV. Current advances in digital cognitive assessment for preclinical Alzheimer\u2019s disease. Alz & Dem Diag Ass & Dis Mo. 2021;13(1):e12217.","journal-title":"Alz & Dem Diag Ass & Dis Mo"},{"issue":"5","key":"1921_CR258","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1080\/13825585.2023.2284412","volume":"31","author":"AJ Aschenbrenner","year":"2024","unstructured":"Aschenbrenner AJ, Jackson JJ. High-frequency assessment of mood, personality, and cognition in healthy younger, healthy older and adults with cognitive impairment. Aging Neuropsychol Cogn. 2024;31(5):914\u201331.","journal-title":"Aging Neuropsychol Cogn"},{"issue":"5","key":"1921_CR259","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1017\/S1355617723011475","volume":"30","author":"MS Welhaf","year":"2024","unstructured":"Welhaf MS, Wilks H, Aschenbrenner AJ, Balota DA, Schindler SE, Benzinger TLS, et al. Naturalistic assessment of reaction time variability in older adults at risk for Alzheimer\u2019s disease. J Int Neuropsychol Soc. 2024;30(5):428\u201338.","journal-title":"J Int Neuropsychol Soc"},{"key":"1921_CR260","doi-asserted-by":"crossref","unstructured":"Vrindha MK, Geethu V, Anurenjan PR, Deepak S, Sreeni KG. A Review of Alzheimer\u2019s Disease Detection from Spontaneous Speech and Text. In: 2023 International Conference on Control, Communication and Computing (ICCC). 2023 [cited 2024 Oct 1]. pp. 1\u20135. Available from: https:\/\/ieeexplore.ieee.org\/document\/10165507","DOI":"10.1109\/ICCC57789.2023.10165507"},{"issue":"3","key":"1921_CR261","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000510820","volume":"4","author":"J Robin","year":"2020","unstructured":"Robin J, Harrison JE, Kaufman LD, Rudzicz F, Simpson W, Yancheva M. Evaluation of speech-based digital biomarkers: review and recommendations. Digit Biomark. 2020;4(3):99\u2013108.","journal-title":"Digit Biomark"},{"key":"1921_CR262","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.620251","volume":"12","author":"I Mart\u00ednez-Nicol\u00e1s","year":"2021","unstructured":"Mart\u00ednez-Nicol\u00e1s I, Llorente TE, Mart\u00ednez-S\u00e1nchez F, Meil\u00e1n JJG. Ten years of research on automatic voice and speech analysis of people with Alzheimer\u2019s disease and mild cognitive impairment: a systematic review article. Front Psychol. 2021;12:620251.","journal-title":"Front Psychol"},{"key":"1921_CR263","doi-asserted-by":"publisher","first-page":"749758","DOI":"10.3389\/fdgth.2021.749758","volume":"3","author":"J Robin","year":"2021","unstructured":"Robin J, Xu M, Kaufman LD, Simpson W. Using digital speech assessments to detect early signs of cognitive impairment. Front Digit Health. 2021;3:749758.","journal-title":"Front Digit Health"},{"issue":"1","key":"1921_CR264","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13195-021-00848-x","volume":"13","author":"A Yeung","year":"2021","unstructured":"Yeung A, Iaboni A, Rochon E, Lavoie M, Santiago C, Yancheva M, et al. Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer\u2019s dementia. Alz Res Ther. 2021;13(1):109.","journal-title":"Alz Res Ther"},{"issue":"2","key":"1921_CR265","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3233\/JAD-150520","volume":"49","author":"KC Fraser","year":"2015","unstructured":"Fraser KC, Meltzer JA, Rudzicz F. Linguistic features identify Alzheimer\u2019s disease in narrative speech. J Alzheimers Dis. 2015;49(2):407\u201322.","journal-title":"J Alzheimers Dis"},{"key":"1921_CR266","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroling.2022.101069","volume":"63","author":"K Chapin","year":"2022","unstructured":"Chapin K, Clarke N, Garrard P, Hinzen W. A finer-grained linguistic profile of Alzheimer\u2019s disease and mild cognitive impairment. J Neurolinguistics. 2022;63:101069.","journal-title":"J Neurolinguistics"},{"key":"1921_CR267","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fpsyg.2017.00269","volume":"8","author":"V Boschi","year":"2017","unstructured":"Boschi V, Catrical\u00e0 E, Consonni M, Chesi C, Moro A, Cappa SF. Connected speech in neurodegenerative language disorders: a review. Front Psychol. 2017;8:269.","journal-title":"Front Psychol"},{"issue":"1","key":"1921_CR268","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1460-6984.12888","volume":"59","author":"O Ivanova","year":"2024","unstructured":"Ivanova O, Mart\u00ednez-Nicol\u00e1s I, Meil\u00e1n JJG. Speech changes in old age: methodological considerations for speech\u2010based discrimination of healthy ageing and Alzheimer\u2019s disease. Int J Lang Commun Disord. 2024;59(1):13\u201337.","journal-title":"Int J Lang Commun Disord"},{"issue":"1","key":"1921_CR269","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13195-024-01543-3","volume":"16","author":"RL Van Den Berg","year":"2024","unstructured":"Van Den Berg RL, De Boer C, Zwan MD, Jutten RJ, Van Liere M, Van De Glind M-CABJ, et al. Digital remote assessment of speech acoustics in cognitively unimpaired adults: feasibility, reliability and associations with amyloid pathology. Alz Res Ther. 2024;16(1):176.","journal-title":"Alz Res Ther"},{"issue":"1","key":"1921_CR270","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12393","volume":"15","author":"I Hajjar","year":"2023","unstructured":"Hajjar I, Okafor M, Choi JD, Moore E, Abrol A, Calhoun VD, et al. Development of digital voice biomarkers and associations with cognition, cerebrospinal biomarkers, and neural representation in early Alzheimer\u2019s disease. Alz & Dem Diag Ass & Dis Mo. 2023;15(1):e12393.","journal-title":"Alz & Dem Diag Ass & Dis Mo"},{"issue":"1","key":"1921_CR271","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1073191116643164","volume":"25","author":"MJ Sliwinski","year":"2018","unstructured":"Sliwinski MJ, Mogle JA, Hyun J, Munoz E, Smyth JM, Lipton RB. Reliability and validity of ambulatory cognitive assessments. Assessment. 2018;25(1):14\u201330.","journal-title":"Assessment"},{"issue":"7","key":"1921_CR272","doi-asserted-by":"publisher","first-page":"e11143","DOI":"10.2196\/11143","volume":"20","author":"N Bott","year":"2018","unstructured":"Bott N, Madero EN, Glenn J, Lange A, Anderson J, Newton D, et al. Device-embedded cameras for eye tracking\u2013based cognitive assessment: validation with paper-pencil and computerized cognitive composites. J Med Internet Res. 2018;20(7):e11143.","journal-title":"J Med Internet Res"},{"issue":"2","key":"1921_CR273","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/1567205014666170829111942","volume":"15","author":"A Konig","year":"2018","unstructured":"Konig A, Satt A, Sorin A, Hoory R, Derreumaux A, David R, et al. Use of speech analyses within a mobile application for the assessment of cognitive impairment in elderly people. CAR. 2018;15(2):120\u20139.","journal-title":"CAR"},{"issue":"1","key":"1921_CR274","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1355617721000199","volume":"28","author":"DW Loring","year":"2022","unstructured":"Loring DW, Bauer RM, Cavanagh L, Drane DL, Enriquez KD, Reise SP, et al. Rationale and design of the National neuropsychology network. J Int Neuropsychol Soc. 2022;28(1):1\u201311.","journal-title":"J Int Neuropsychol Soc"},{"key":"1921_CR275","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2024.1452462","volume":"15","author":"J-CA Finley","year":"2024","unstructured":"Finley J-CA. Performance validity testing: the need for digital technology and where to go from here. Front Psychol. 2024;15:1452462.","journal-title":"Front Psychol"},{"issue":"1","key":"1921_CR276","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s43621-024-00217-2","volume":"5","author":"Z Jahan","year":"2024","unstructured":"Jahan Z, Khan SB, Saraee M. Early dementia detection with speech analysis and machine learning techniques. Discov Sustain. 2024;5(1):65.","journal-title":"Discov Sustain"},{"key":"1921_CR277","unstructured":"Hazra P, Podder S, Das S, Chakraborty T, Dhara AK, Bera TK. Power of words: A review of approaches utilizing speech and text for Alzheimer\u2019s disease detection. J Syst Eng Electron. 2024;34(5):259\u201371."},{"key":"1921_CR278","doi-asserted-by":"crossref","unstructured":"Jeong H, Jeong YW, Park Y, Kim K, Park J, Kang DR. Applications of deep learning methods in digital biomarker research using noninvasive sensing data. Digit Health. 2022;8205520762211366.","DOI":"10.1177\/20552076221136642"},{"key":"1921_CR279","unstructured":"Sch\u00e4fer S, Herrmann J, Tovar S, Linz N, Tr\u00f6ger J. Speech-Based digital biomarkers for Alzheimer\u2019s research. In: Perneczky R, editor Biomarkers for alzheimer\u2019s disease drug development. New York, NY: Springer US."},{"issue":"8","key":"1921_CR280","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/alz.12297","volume":"17","author":"A Rodrigo","year":"2021","unstructured":"Rodrigo A, Trigueros P, Jamilis L, Alegret M, Rodr\u00edguez O, T\u00e1rraga L, et al. Identification of undiagnosed dementia cases using a web-based pre\u2010screening tool: The MOPEAD project. Alzheimer\u2019s & Dementia. 2021;17(8):1307\u201316.","journal-title":"Alzheimer's & Dementia"},{"issue":"12","key":"1921_CR281","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41582-024-01033-y","volume":"20","author":"MH Gramkow","year":"2024","unstructured":"Gramkow MH, Waldemar G, Frederiksen KS. The digitized memory clinic. Nat Rev Neurol. 2024;20(12):738\u201346.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1921_CR282","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.14283\/jpad.2024.103","volume":"11","author":"SA Lott","year":"2024","unstructured":"Lott SA, Streel E, Bachman SL, Bode K, Dyer J, Fitzer-Attas C, et al. Digital health technologies for Alzheimer\u2019s disease and related dementias: initial results from a landscape analysis and community collaborative effort. The Journal of Prevention of Alzheimer\u2019s Disease. 2024;11(5):1480\u20139.","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"3","key":"1921_CR283","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ana.26833","volume":"95","author":"KV Papp","year":"2024","unstructured":"Papp KV, Jutten RJ, Soberanes D, Weizenbaum E, Hsieh S, Molinare C, et al. Early detection of amyloid-related changes in memory among cognitively unimpaired older adults with daily digital testing. Ann Neurol. 2024;95(3):507\u201317.","journal-title":"Ann Neurol"},{"issue":"1","key":"1921_CR284","doi-asserted-by":"publisher","first-page":"12081","DOI":"10.1038\/s41598-022-15874-4","volume":"12","author":"F Lipsmeier","year":"2022","unstructured":"Lipsmeier F, Taylor KI, Postuma RB, Volkova-Volkmar E, Kilchenmann T, Mollenhauer B, et al. Reliability and validity of the Roche PD mobile application for remote monitoring of early parkinson\u2019s disease. Sci Rep. 2022;12(1):12081.","journal-title":"Sci Rep"},{"key":"1921_CR285","unstructured":"Neurotrack [Internet]. Neurotrack. Available from: https:\/\/neurotrack.com\/"},{"key":"1921_CR286","unstructured":"Ruhmel S, Speech Biomarkers. A New Tool in Alzheimer\u2019s Disease Clinical Trials. Available from: https:\/\/www.janssen.com\/blogs\/speech-biomarkers-toll-alzheimer-disease"},{"key":"1921_CR287","unstructured":"ICER-PHTI Assessment Framework for Digital Health Technologies [Internet]. Peterson Health Technology Institute. 2023 Sep [cited 2024 Nov 30]. Available from: https:\/\/phti.com\/wp-content\/uploads\/sites\/3\/2023\/09\/ICER-PHTI-Assessment-Framework-for-Digital-Health-Technologies-1.0.pdf"},{"key":"1921_CR288","doi-asserted-by":"crossref","unstructured":"Goldsack JC, Coravos A, Bakker JP, Bent B, Dowling AV, Fitzer-Attas C et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for biometric monitoring technologies (BioMeTs). NPJ Digit Med. 2020;3:55.","DOI":"10.1038\/s41746-020-0260-4"},{"issue":"8","key":"1921_CR289","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Fowler NR. Alzheimer disease blood biomarkers: considerations for population-level use. Nat Rev Neurol. 2024;20(8):495\u2013504.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1921_CR290","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-244X-14-84","volume":"14","author":"B Poblador-Plou","year":"2014","unstructured":"Poblador-Plou B, Calder\u00f3n-Larra\u00f1aga A, Marta-Moreno J, Hancco-Saavedra J, Sicras-Mainar A, Soljak M, et al. Comorbidity of dementia: a cross-sectional study of primary care older patients. BMC Psychiatry. 2014;14(1):84.","journal-title":"BMC Psychiatry"},{"key":"1921_CR291","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.631770","author":"JA Santiago","year":"2021","unstructured":"Santiago JA, Potashkin JA. The impact of disease comorbidities in Alzheimer\u2019s disease. Front Aging Neurosci. 2021. https:\/\/doi.org\/10.3389\/fnagi.2021.631770.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1921_CR292","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14283\/jpad.2024.32","volume":"11","author":"K Malzbender","year":"2024","unstructured":"Malzbender K, Barbarino P, Ferrell PB, Bradshaw A, Brookes AJ, D\u00edaz C, et al. Validation, deployment, and real-world implementation of a modular toolbox for Alzheimer\u2019s disease detection and dementia risk reduction: the AD-RIDDLE project. J Prev Alzheimers Dis. 2024;11(2):329\u201338.","journal-title":"J Prev Alzheimers Dis"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01921-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:04:03Z","timestamp":1768482243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01921-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":292,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01921-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MS has served\/serves on advisory boards for Arvakor, Eli Lilly and Company, Novo Nordisk and Roche, received honoraria for presentations or educational material from Bioarctic, Novo Nordisk, Eli Lilly and Company, Roche and Triolabs, and receives research support (to the institution) from Beckman Coulter, Bioarctic, Novo Nordisk and Roche. He is co-founder and shareholder of Centile Bioscience and serves as Associate Editor with Alzheimer\u2019s Research & Therapy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}